Corvus Pharmaceuticals (CRVS) to Release Earnings on Monday

Posted by MarketBeat News on May 5th, 2024

Corvus Pharmaceuticals (NASDAQ:CRVS – Get Free Report) will be releasing its earnings data after the market closes on Monday, May 6th. Analysts expect Corvus Pharmaceuticals to post earnings of ($0.12) per share for the quarter. Persons that are interested in participating in the company’s earnings conference call can do so using this link.

Corvus Pharmaceuticals (NASDAQ:CRVS – Get Free Report) last issued its earnings results on Tuesday, March 19th. The company reported ($0.14) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.14). On average, analysts expect Corvus Pharmaceuticals to post $0 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Corvus Pharmaceuticals Trading Up 11.0 %

NASDAQ:CRVS opened at $1.92 on Friday. The company’s 50 day moving average price is $1.80 and its 200-day moving average price is $1.77. Corvus Pharmaceuticals has a 52 week low of $1.05 and a 52 week high of $4.19.

Analyst Ratings Changes

Want More Great Investing Ideas?

CRVS has been the topic of several analyst reports. Oppenheimer lowered their price objective on Corvus Pharmaceuticals from $8.00 to $7.00 and set an “outperform” rating on the stock in a research report on Wednesday, March 20th. Mizuho reaffirmed a “neutral” rating and set a $3.50 price target on shares of Corvus Pharmaceuticals in a report on Wednesday, March 27th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Corvus Pharmaceuticals in a report on Monday, April 1st.

View Our Latest Report on Corvus Pharmaceuticals

Corvus Pharmaceuticals Company Profile

(Get Free Report)

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis.